MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly.

Abstract

Acromegaly is associated with high morbidity and elevated mortality when not adequately treated. Surgery is the first-line treatment for most patients as it is the only one that can lead to immediate cure. In patients who are not cured by surgery, treatment is currently based on a trial-and-error approach. First-generation somatostatin receptor ligands (fg-SRL) are initiated for most patients, although approximately 25% of patients present resistance to this drug class. Some biomarkers of treatment outcome are described in the literature, with the aim of categorizing patients into different groups to individualize their treatments using a personalized approach. In this review, we will discuss the current status of precision medicine for the treatment of acromegaly and future perspectives on the use of personalized medicine for this purpose.

• Authors: Leandro Kasuki, Luiz Eduardo Wildemberg, Mônica R Gadelha
• Journal: European journal of endocrinology (Eur J Endocrinol) Vol. 178 Issue 3 Pg. R89-R100 (Mar 2018) ISSN: 1479-683X [Electronic] England
• PMID: 29339530 (Publication Type: Journal Article, Review)
• Copyright: © 2018 European Society of Endocrinology.

Chemical References

• Dopamine Agonists
• Receptors, Somatotropin
• Somatostatin

Topics

• Acromegaly (drug therapy)
• Adenoma (drug therapy)
• Dopamine Agonists (therapeutic use)
• Growth Hormone-Secreting Pituitary Adenoma (drug therapy)
• Humans
• Precision Medicine
• Receptors, Somatotropin (antagonists & inhibitors)
• Somatostatin (analogs & derivatives)
• Treatment Outcome